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compression. Moreover, the complication rate appears similar for
interventional procedures for the market-leading products, Angio-
Seal and Perclose, with a higher complication rate seen with the
VasoSeal device (1).
As with other interventional technologies, an evolution has
occurred in closure device technology that outpaces the published
data. In our own portfolio of Perclose suture closure products, key
improvements have been seen with each generation of product.
The Closer product was introduced in 1999 and saw a fundamental
change with needles that captured suture from above the arteriot-
omy rather than having a platform where needles were actually
positioned in the artery and delivered suture to the surface. We
believe that the Closer provided a patient safety feature and greater
reliability, which may not have been reflected in the meta-analysis,
which included 15 Perclose-related studies on the older TechStar
and ProStar product lines reported by Nikolsky. A more recent
patient set was examined by Tavris et al. (2), where analysis of the
large ACC-NCDR database of 166,680 patients saw a reduction
in vascular complications and death in patients who had the
Angio-Seal and Perclose vascular closure devices used when
compared to manual compression or compression devices. This
finding was assessed from patient data collected between 2001 and
2002.
Similarly, a meta-analysis may not reflect a change in practice
style or technique, which might be better detected in a randomized
clinical trial or database survey. Of the 15 Perclose studies
examined, only 4 were with 6- to 7-F sheaths; the others were
actually larger sheath sizes, which is uncommon in practice over
the past five to six years. Suture-based devices in particular have
been commonly used in larger-diameter puncture sites. Closure
devices have reduced their size as practice patterns have moved
toward a smaller dimension, and this shift may be reflected in
outcomes seen with the newer devices as well as with manual
compression with or without a compression-assist device.
Despite the criticisms mentioned above, the Nikolsky et al. (1)
study is an important signal for our field. Although no study is
perfect, reports such as those by Nikolsky et al. (1) and Tavris et al.
(2) have shown that the predominant technologies on the market
are equivalent and potentially superior to manual compression in
providing patient comfort and safety. Higher-risk clinical scenarios
have to be considered, especially in the female patient (3); however,
the time may be ripe for more study and a head-to-head random-
ized clinical trial.
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REPLY
We reviewed carefully the comments of Dr. Chou regarding our
recent study (1). A meta-analysis always has several limitations,
which we listed in the respective section of our report and which
Dr. Chou outlines in his letter. The main issue of the multiple
small size, uncontrolled, and often unpublished (as complete
papers) studies in the area of vascular closure devices can be
attributed to the existence of multiple generations of all devices
and to the funding variability (or difficulty to obtain adequate
research grants from industry). Similarly, a database analysis (2) is
also limited by the uncontrolled, rather random (and certainly
nonconsecutive) data entry and the absence of event review and
adjudication by an independent committee. Moreover, Dr. Chou’s
claim that more recent-generation devices are included is a very
reasonable presumption but is not explicitly documented. These
limitations of the way the queried database is set up have nothing
to do with the elegant way the data were handled by Tavris et al.
(2) but still deserve to be outlined.
Therefore, we do not believe that adequate reasons exist to
declare one type of analysis “more meaningful” than the other, but
we certainly endorse the expressed interest by a major industry
stakeholder for a large, randomized study. This is what is needed
the most in this subject.
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Heart Failure Training: Care for
Older Adults With Chronic Heart Failure
Studies by Adamson et al. (1) and Konstam (2) eloquently
highlight the need for heart failure (HF) specialists. As drug and
device therapies for HF are rapidly evolving, it is difficult even for
cardiologists to stay abreast of. Internists, family physicians, and
geriatricians, who treat the vast majority of HF patients, often
underutilize angiotensin-converting enzyme (ACE) inhibitors or
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beta-blockers (3). Over 80% of HF patients are 65 years of age and
older (4); they are often women, have preserved systolic function,
suffer from multiple comorbidities, and receive care in nonaca-
demic settings.
The quality of primary care provided by cardiologists is un-
known (5). Yet, a 35-year-old young man with systolic HF and no
other comorbidities might receive optimum total care from a
general cardiologist. However, a 75-year-old woman with HF and
multiple comorbidities might benefit more if cared for by a primary
care physician in collaboration with a cardiologist. Treatment of
older adults is particularly the most complicated. For example, an
elderly HF patient might receive the best HF care from a
cardiologist, yet an undiagnosed or untreated osteoarthritis or
depression might compromise her quality of life.
Given the HF epidemic, it is not possible for cardiologists to
provide total care to HF patients. It is unlikely that training HF
specialists will improve the quality of care or quality of life of these
patients. A complementary approach might be: 1) building alli-
ances with national organizations for primary care physicians to
develop innovative strategies to educate these physicians about the
advances in the pharmacological management of HF, and 2)
encouraging policies that would reward hospitals and clinicians
who follow HF quality indicators similar to those developed by the
Centers for Medicare and Medicaid Services and the Joint Com-
mission on Accreditation of Healthcare Organizations (6). Pri-
mary care physicians are capable of evaluating left ventricular
function and prescribing ACE inhibitors and beta-blockers to
eligible patients with systolic dysfunction. However, patients
should be referred to cardiologists, at least once during the initial
evaluation, for assessment of coronary artery disease, possible
coronary revascularization, and valvular heart disease. The Amer-
ican College of Cardiology/American Heart Association guide-
lines for chronic HF has identified this collaborative model as the
most preferred one for HF care (7).
A complementary model of training might involve training
primary care physicians for one year similar to the one-year clinical
geriatric fellowship. Training should involve outpatient and inpa-
tient evaluation and management of HF with additional exposure
to echocardiography and nuclear cardiology. During my research
fellowship in geriatric medicine, I received clinical training in HF
at the University of Alabama (UAB) Advanced HF Clinic.
Subsequently, in collaboration with cardiology, I developed two
Geriatric HF Clinics at UAB and the Veterans Affairs Medical
Center, which provide comprehensive care to older adults with
HF. Organizations dedicated in advancing HF training and
treatment should promote parallel programs to train general HF
specialists alongside cardiology HF specialists. The former group is
likely to have the greatest impact on improving the overall quality
of care and life of the vast majority of our HF patients.
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REPLY
I appreciate the comments of Dr. Ahmed regarding my recent
report advocating developing subspecialty training in heart failure
(1). I interpret Dr. Ahmed’s remarks as acknowledging the need
for more formalized training and certification in this area, given
the expanding population with heart failure (HF), and given the
increasing complexity of available diagnostic and treatment op-
tions. However, Dr. Ahmed raises some important caveats. He
rightfully points out that a large percentage of patients with HF
will continue to be treated by physicians who are not cardiologists.
He also correctly emphasizes the value of primary care physicians
and geriatricians in managing patients who carry an HF diagnosis
but have a high prevalence of comorbidity.
As I state in my report, various steps are needed to meet the
needs of patients with HF. These steps include guideline-driven
educational efforts, disease-management strategies, and “more
efficient systems of referral and communication, with sharing of
care management between the specialist and the primary care
provider.”
However, these points do not negate the value of encouraging
specialization within this increasingly complex field, as a critical
step toward improving quality of care for HF patients. Further, as
I mention in my report, “All of the skills obtained through general
cardiology training are invaluable as an underpinning for subspe-
cialization in heart failure.” These skills include a detailed under-
standing of hemodynamics, cardiac imaging, cardiac arrhythmias,
valvular and ischemic heart disease, the indications for complex
cardiovascular procedures, and management of patients who have
undergone such procedures.
Improving quality of care in HF, as in any area, requires a
multi-pronged approach. We need both improved systems and
improved education of all physicians and nurses who will contrib-
ute to the care of these patients. Educational and training
programs directed toward general internists, family medicine
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